References
- Abrahams E. Right drug – right patient – right time: personalized medicine coalition. Clin Transl Sci. 2008;1(1):11–12.
- Metzker ML. Sequencing technologies – the next generation. Nat Rev Genet 2010;11(1):31–46.
- IOM (Institute of Medicine). Evolution of translational omics: Lessons learned and the path forward. Washington (DC): The National Academies Press; 2012. Available from: https://www.nap.edu/initiative/committee-on-the-review-of-omics-based-tests-for-predic-ting-patient-outcomes-in-clinical-trials.
- McShane LM, Cavenagh MM, Lively TG, et al. Criteria for the use of omics-based predictors in clinicaltrials. Nature. 2013;502:317–320.
- Sullivan DC, Bresolin L, Seto B, et al. Introduction to metrology series. Stat Methods Med Res. 2015;24:3–8.
- Bohr A, Memarzadeh K. Chapter 2 - The rise of artificial intelligence in healthcare applications. In: Artificial intelligence in healthcare. Academic Press; 2020. p. 25–60. Available from: https://www.sciencedirect.com/science/article/pii/B9780128184387000022?via%3Dihub
- Evans RS. Electronic health records: then, now, and in the future. Yearb Med Inform. 2016 May 20;Suppl 1(Suppl 1): S48–S61. doi:https://doi.org/10.15265/IYS-2016-s006
- Sadée W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005;14(2):R207–R214.
- U.S. Food and Drug Administration. Qualification process for drug development tools guidance for industry and FDA staff. 2020 [cited 2021 March 2]. Available from: https://www.fda.gov/media/133511/download.
- U.S. Food and Drug Administration. Qualification of medical device development tools guidance for industry, tool developers, and food and drug administration staff. 2017 August 10 [cited 2021 March 2]. Available from: https://www.fda.gov/media/87134/download.
- 21st Century Cures Act. H.R. 34, 114th Congress. 2016. 7. [cited 2017 February 1].
- U.S. Food and Drug Administration. Paving the way for personalized medicine: FDA’s role in a new era of medical product development. 2013. Available from: http://www.fda.gov/down-loads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf.
- U.S. Food and Drug Administration. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD). 2020 [updated December 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326791/.
- European Union Council. IV. Notices From European Union Institutions, Bodies, Offices And Agencies Council: Council conclusions on personalised medicine for patients, (2015/C 421/03). 2015. https://op.europa.eu/en/publication-detail/-/publication/f416ce37-a48c-11e5-b528-01aa75ed71a1/language-en.
- Ehmann F, Caneva L, Prasad K, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015;15:201–210.
- European Medicines Agency. Regulatory Science Strategy to 2025. 2020 [cited January 2021]. Available from: https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-strategyregulatory-science-strategy-to-2025-section.
- Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364:1144–1153.
- U.S. Food and Drug Administration. Substantial equivalence determination decision summary, 510(k) number k042259, AmpliChip CYP450 microarray, Genotype of Cytochrome P450 2D6 (CYP2D6). 2005 [cited February 24, 2021]. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K042259.pdf.
- U.S. Food and Drug Administration. Substantial equivalence determination decision summary, 510(k) number k043576, AmpliChip CYP450 microarray, Genotype of Cytochrome P450 2C19 (CYP2C19). 2005 [cited February 24, 2021]. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K043576.pdf.
- Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(1):391–396.
- Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89–295.
- Zanger UM, Schwab M. Cytochrome p450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
- Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765.
- Peeters M, Price T, Hotko Y, et al. 14LBA randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Eur J Cancer Suppl. 2009;7:10. Abstract 14LBA.
- U.S. Food and Drug Administration, Summary of Safety and Effectiveness Data (SSED). PMA Number P110027, therascreen® KRAS RGQ PCR Kit, by QIAGEN Manchester Ltd. 2014 [cited 2021 Feb 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110027B.pdf.
- Hayes DF. HER2 and Breast cancer – A phenomenal success story. N Engl J Med. 2019;381(13):1284–1286.
- U.S. Food and Drug Administration, Summary of Safety and Effectiveness Data (SSED). PD-L1 IHC 28-8 pharmDx, Premarket Approval Application (PMA) Number: P150025/S013. 2020 [cited 2021 Feb 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf15/P1500-25S013B.pdf.
- U.S. Food and Drug Administration. 510(k) Substantial equivalence determination decision summary. 510(k) number K062694, De Novo number DEN070009, Mammaprint, by Agendia, BV. 2020 [cited 2021 Feb 25]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN070009.; https://www.accessdata.fda.gov/cdrh_docs/revi-ews/k062694.pdf.
- Drier Y, Domany E. El-Rifai W. Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? PLoS ONE. 2011;6(3):e17795.
- Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nature Machine Intelligence. 2019;1:206–215.
- U.S. Food and Drug Administration. Evaluation of Automatic Class III Designation for QuantX: Decision Summary, De Novo DEN170022. 2017 [cited 2021 Feb 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170022.pdf.
- U.S. Food and Drug Administration. Evaluation of Automatic Class III Designation for ContaCT: Decision Summary, De Novo DEN170073. 2018 [cited 2021 Feb 25]. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170073.pdf.
- U.S. Food and Drug Administration. FDA permits marketing of clinical decision support software for alerting providers of a potential stroke in patients.2018 [cited 2021 Feb 25]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm596575.htm.
- Knowles L, Luth W, Bubela T. Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. J Law Biosci. 2017; 4:453–506.
- Horgan D, Jansen M, Leyens L, et al. An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. Public Health Genom. 2014;17(5–6):287–298.
- Tang R, Pennello G. Validation of prognostic marker tests: Statistical lessons learned from regulatory experience. Ther Innov Regul Sci. 2016;50(2):241–252.
- Schulman KA, Tunis SR. A policy approach to the development of molecular diagnostic tests. Nat Biotechnol. 2010;28:1157–1159.
- Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat. 2009;3(4):1309–1334.
- McShane LM, Polley MY. Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility. Clin Trials. 2013;10:653–665.
- Simon R, Simon N. Finding the intended use population for a new treatment. J Biopharmaceutical Statistics. 2019;29(4):675–684.
- Lyman GH, Moses HL. Biomarker tests for molecularly targeted therapies – the key to unlocking precision medicine. N Engl J Med. 2016;375(1):4–6.
- U.S. Food and Drug Administration. In vitro companion diagnostic devices guidance. 2014 August 6 [cited 2021 January 17]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitrocompanion-diagnostic-devices.
- U.S. Food and Drug Administration. Principles for codevelopment of an in vitro companion diagnostic device with a therapeutic product: draft guidance. 2016 July 15 [cited 2021 January 17]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-docu-ments/principlescodevelopment-vitro-companion-diagnostic-device-therapeutic-product.